Lung Cancer Surgery in Canada Trends and Forecast
The future of the lung cancer surgery market in Canada looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets. The global lung cancer surgery market is expected to reach an estimated $5.7 billion by 2031 with a CAGR of 3.4% from 2025 to 2031. The lung cancer surgery market in Canada is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.
• Lucintel forecasts that, within the product type category, surgical device is expected to witness the highest growth over the forecast period.
• Within the end use category, ambulatory surgical center is expected to witness the highest growth over the forecast period.
Emerging Trends in the Lung Cancer Surgery Market in Canada
Canada’s lung cancer surgery sector is advancing swiftly, driven by public health initiatives, technological innovation, and changing practice patterns. As lung cancer remains a leading cause of cancer mortality, screening pilots funded by Health Canada are increasing early-stage detection, fueling demand for surgical intervention. Major academic centers now routinely use minimally invasive techniques such as VATS and robotic surgery. In tandem, AI-driven imaging and intraoperative guidance are enhancing precision. Despite challenges—like slower robotic adoption and regional disparities—Canada’s universal health system and collaborative research environment are setting the stage for more accessible and advanced thoracic oncology care.
• Widespread Adoption of VATS (Video‑Assisted Thoracoscopic Surgery): VATS is now the standard for the majority of lung cancer resections in Canada, offering benefits like smaller incisions, reduced pain, and shorter hospital stays. Its broader adoption across centers in Ontario, Quebec, and British Columbia improves recovery and lowers perioperative morbidity. Enhanced training programs support its expansion into regional hospitals, reducing the need for thoracotomy and increasing patient access to minimally invasive surgery.
• Robotic-Assisted Thoracic Surgery (RATS) Gaining Traction via Trials: While Canada lagged in robotic uptake, several centers (e.g., St. Joseph’s Hamilton, Kingston) have launched thoracic robotic programs through research initiatives. These programs suggest RATS offers finer instrument control and better lymph node dissection. Ongoing randomized trials comparing RATS to VATS are evaluating cost-effectiveness, recovery outcomes, and quality of life. The evidence from these studies could accelerate robotic surgery’s integration into Canada’s publicly funded healthcare system.
• Early Integration of AI and Imaging Tools for Screening & Planning: AI-driven analysis of CT scans and biomarkers aims to enhance early detection and assist in precise surgical planning. Canadian Cancer Society-funded AI tools are being developed to identify malignancy risk and CT findings, streamlining referral and diagnostic processes. Intraoperative imaging enhancements are also being introduced, improving margin precision and operative efficiency. These tools support more accurate, tailored surgical care and optimized resource use.
• Enhanced Recovery After Surgery (ERAS) Protocols Becoming Standard: Canadian thoracic centers are adopting ERAS pathways—standardized care protocols designed to decrease complications, support early mobilization, and reduce length of stay. ERAS guidelines are now routinely implemented alongside VATS and emerging robotic procedures, enabling faster recovery and reducing perioperative resource use. The protocols are aligned with efforts to shift suitable lung cancer surgeries toward short-stay or outpatient settings.
• National Lung Cancer Screening Pilots Enable More Surgical Treatment: Province-wide low-dose CT screening pilots in Ontario and British Columbia are increasing early-stage lung cancer diagnoses. Earlier detection shifts treatment eligibility toward surgical resection, particularly via minimally invasive methods. These pilots are paired with multidisciplinary networks to coordinate pre-surgical assessment and post-surgical care. As these programs scale up, they reinforce demand for advanced surgical capabilities and help strengthen referral pathways across Canada.
Canada’s lung cancer surgery market is being reshaped by minimally invasive practices, emerging robotic platforms, AI-guided screening, ERAS adoption, and increased early detection. These trends are enhancing care quality, expanding access, and optimizing outcomes. As evidence accumulates—especially around robotic efficacy and AI tools—Canada’s healthcare system is poised to deliver more precise, efficient, and equitable lung cancer surgical care nationwide.
Recent Developments in the Lung Cancer Surgery Market in Canada
Canada is transforming its lung cancer surgery infrastructure through targeted technological investment, evidence-based trials, and early detection initiatives. Enhanced screening, launch of robotic surgery programs, ERAS implementation, and AI research are converging to streamline patient pathways and elevate surgical care. Together, they position Canada to better manage lung cancer with timely and effective intervention.
• Launch of Robotic Thoracic Programs in Regional Centers: Hospitals such as Kingston Health Sciences Centre and St. Joseph’s Hamilton have launched robotic-assisted thoracic programs. These recent deployments enable thoracic surgery via minimally invasive robotic platforms outside major urban hubs. Early results reveal improved lymph node dissection capability and reduced post-op pain. These initiatives are supported by international mentorship and philanthropic funding, setting the foundation for regional expansion of thoracic robotics.
• Ongoing RCT Comparing VATS vs RATS: An important randomized trial at McMaster and partners is directly comparing VATS and RATS for early-stage NSCLC. By analyzing quality of life and cost utility in publicly funded settings, the study seeks to inform policy decisions. This first-of-its-kind Canadian trial will guide surgical choices and influence funding priorities, potentially accelerating the adoption of robotics if demonstrated to be cost-effective and clinically superior.
• Advancements in AI Detection and Planning: Canadian Cancer Society-supported teams are developing AI models to identify malignancy risk from CT scans and biomarkers. These tools improve early detection and refine surgical planning. Concurrently, pilot projects using imaging AI assist surgeons in delineating tumor margins intraoperatively. These efforts aim to streamline referral processes, reduce diagnostic delays, and enhance surgical precision.
• Implementation of ERAS Pathways Across Thoracic Programs: Canadian thoracic units have introduced Enhanced Recovery After Surgery (ERAS) protocols for lung resection, focusing on pain control, mobility, and nutrition. Application across both VATS and robotic cases has reduced hospital stays and complication rates. This standardization supports consistent, efficient surgical care and helps transition suitable cases to short-stay or outpatient models without sacrificing safety.
• Scale-up of Low-Dose CT Screening Pilots: Ontario and British Columbia have begun province-wide lung cancer screening pilots targeting high-risk individuals via low-dose CT. These early detection efforts are identifying more operable tumors, catalyzing demand for minimally invasive interventions. Integrated care pathways support timely surgical referral and improve multidisciplinary coordination—enhancing overall treatment effectiveness and survival outcomes.
Recent Canadian developments—robotic program expansion, randomized trials, AI innovations, ERAS implementation, and lung screening pilots—are collectively enhancing the national capacity for lung cancer surgery. This integrated emphasis is transforming care delivery toward more precise, timely, and equitable models, setting a strong foundation for improved outcomes and system efficiency.
Strategic Growth Opportunities for Lung Cancer Surgery Market in Canada
Canada’s lung cancer surgery market is experiencing transformation driven by increased early-stage detection, growing demand for minimally invasive procedures, and the adoption of digital technologies. The country’s public healthcare infrastructure supports broad access, while investments in clinical innovation continue to reshape surgical practices. Five key application-based opportunities are emerging across thoracoscopic surgery, robotics, outpatient care, AI-guided planning, and telehealth recovery. These developments are collectively improving patient outcomes, lowering complication rates, and ensuring equitable access to modern thoracic surgical solutions across Canada.
• Expansion of Minimally Invasive Thoracoscopic Surgery (VATS): Minimally invasive thoracoscopic surgery is rapidly becoming a preferred approach for early-stage lung cancer cases across Canadian provinces. This technique leads to faster recovery, shorter hospital stays, and reduced postoperative complications. Its adoption is being promoted through specialized surgical training programs and hospital investments in advanced endoscopic tools. Medical device manufacturers offering reusable and cost-effective VATS kits can benefit from this shift. Expansion into regional healthcare centers ensures that patients outside urban hubs also gain access to high-quality surgical care.
• Introduction of Robotic-Assisted Thoracic Surgery (RATS): Robotic-assisted surgery is gaining ground in Canada’s academic and research hospitals, particularly in large metropolitan centers. Robotic systems improve surgical precision and reduce fatigue for thoracic surgeons. While initial capital investment remains high, increasing interest in robotic platforms is encouraging hospitals to pursue public-private partnerships and funding initiatives. Suppliers providing training, service support, and flexible acquisition models will be well positioned to serve hospitals transitioning toward robotic thoracic procedures and expand access beyond urban institutions.
• Emergence of Outpatient and Ambulatory Surgery Models: Canadian healthcare systems are testing outpatient thoracic surgery programs, particularly for segmentectomy and lobectomy cases. This shift enables quicker recovery and reduces hospital resource consumption. These models rely on streamlined surgical protocols, mobile postoperative monitoring, and efficient perioperative care. Medical suppliers providing compact surgical platforms and postoperative care kits can help hospitals expand outpatient services. Adoption of ambulatory surgery models aligns with national objectives to improve healthcare efficiency and accessibility.
• Use of AI-Based Surgical Planning and Imaging Tools: Artificial intelligence is being deployed to enhance preoperative imaging and surgical planning for lung cancer resection. AI improves identification of small tumors and supports better targeting of surgical margins. Hospitals are increasingly investing in AI-enabled software to reduce surgical risk and improve precision. Technology providers offering imaging platforms that integrate seamlessly with existing hospital systems will play a key role in shaping digital transformation in thoracic oncology. These tools contribute to improved surgical outcomes and more accurate lung resections.
• Growth in Telehealth for Postoperative Monitoring: Postoperative follow-up through telehealth is expanding in Canada to improve continuity of care for lung cancer patients, particularly those in rural areas. Virtual recovery platforms enable monitoring of pain, breathing function, and surgical site conditions, reducing unnecessary readmissions. Healthcare providers are integrating telehealth into discharge protocols, and this is opening demand for connected monitoring devices and cloud-based support platforms. Vendors that can deliver secure, user-friendly, and interoperable telehealth solutions will benefit from growing adoption across provinces.
Canada’s lung cancer surgery market is experiencing growth through the expansion of minimally invasive methods, adoption of robotics, outpatient models, AI-driven planning, and telehealth services. These opportunities are improving surgical outcomes, enhancing system efficiency, and making advanced care more accessible nationwide. As hospitals and health systems continue to modernize their thoracic programs, vendors aligned with these priorities will find long-term, scalable opportunities in the Canadian market.
Lung Cancer Surgery Market in Canada Driver and Challenges
Canada’s lung cancer surgery market is influenced by a range of technological, economic, and regulatory dynamics. Publicly funded healthcare supports patient access, while national screening efforts are raising early-stage detection. At the same time, innovation in imaging, robotics, and digital health is fueling transformation in surgical practices. However, cost pressures, geographic disparities, and surgeon training limitations remain barriers. A focused approach to enabling innovation while ensuring access and sustainability is critical to achieving meaningful, system-wide improvements.
The factors responsible for driving the lung cancer surgery market in Canada include:
• Supportive Public Healthcare Infrastructure: Canada’s universal healthcare model ensures patients have access to cancer diagnostics and surgery regardless of income or region. Lung cancer surgery is covered under provincial health plans, which provides consistent reimbursement and enables hospitals to invest in modern surgical technologies. This funding model offers a stable environment for vendors and care providers to introduce new innovations. It also facilitates procurement of surgical devices and systems that can improve efficiency and outcomes without burdening patients with financial barriers.
• Wider Implementation of Lung Cancer Screening Programs: The rollout of low-dose CT screening programs across several provinces is increasing the number of early-stage lung cancer diagnoses. Early detection significantly raises the number of patients eligible for surgical resection. This is expanding demand for both conventional and minimally invasive thoracic surgeries. As screening adoption continues to rise, hospitals and clinics will require more operating room capacity, skilled personnel, and modern surgical instruments. Vendors aligned with this increase in procedural volume will benefit from sustained demand.
• Favorable Innovation and Research Ecosystem: Government-funded institutions in Canada are promoting the adoption of innovative surgical technologies. Supportive grant systems and research incentives are accelerating clinical trials of AI systems, robotic platforms, and novel surgical devices. Regulatory processes for new technologies are also becoming more streamlined. This pro-innovation climate offers opportunities for companies to test and scale solutions within academic health networks. Technology providers that collaborate closely with leading centers can gain first-mover advantage and drive early adoption.
• Growing Investments in Robotic Surgery Platforms: Although robotic systems require high capital investment, academic hospitals and surgical centers are investing in them for their precision and surgeon comfort benefits. Clinical trials and philanthropic contributions are helping mitigate cost concerns, allowing selective deployment in high-volume centers. These investments are setting the stage for future expansion into other hospitals. Suppliers that provide scalable robotic systems, ongoing training, and service contracts can benefit from growing interest in robotics as part of thoracic surgery programs.
• Influence of Centralized Procurement Systems: Procurement in Canada’s healthcare system is often coordinated through provincial authorities or regional health networks. This centralized model gives vendors the opportunity to negotiate multi-site contracts and deploy solutions at scale. Working with procurement decision-makers early can support faster adoption of new surgical products and ensure alignment with health system goals. Vendors that offer cost-effective, validated solutions stand to gain access to larger hospital networks through unified procurement strategies.
Challenges in the lung cancer surgery market in Canada are:
• High Costs of Advanced Surgical Equipment: Advanced technologies like robotic systems and AI planning tools are associated with high upfront and ongoing costs. Many regional or smaller hospitals are unable to invest in these tools due to limited budgets. This cost barrier restricts widespread adoption of innovative procedures. Companies must consider offering flexible pricing models, such as leasing or outcome-based contracts, to increase accessibility. Addressing affordability is key to ensuring that innovation reaches all parts of the healthcare system.
• Shortage of Skilled Thoracic Surgeons and Training Gaps: There is a shortage of trained thoracic surgeons across Canada, especially in rural and less populated provinces. In addition, many surgical residents lack access to robotic or minimally invasive training modules. These workforce limitations hinder the rollout of advanced surgical techniques. Addressing this challenge will require expansion of training programs, simulation tools, and mentorship opportunities. Vendors who provide integrated training support with their products can help bridge the skills gap and accelerate technology adoption.
• Geographic and Regional Disparities in Access: Access to lung cancer surgery is uneven across Canada, with patients in rural or remote communities often facing long travel distances and limited specialist availability. This disparity results in delayed care and reduced outcomes for certain populations. Expanding telehealth consultations, mobile surgical services, and regional training initiatives can improve equity. Solutions that support care decentralization and virtual follow-up will be crucial to overcoming this longstanding challenge and expanding reach across underserved regions.
Canada’s lung cancer surgery market is supported by a strong healthcare infrastructure, increasing early-stage detection, and an encouraging environment for innovation. Despite cost and workforce barriers, there are significant opportunities to scale modern surgical approaches across the country. Addressing regional disparities and expanding access through technology, training, and smart procurement will be vital to ensuring sustainable growth and improving care outcomes nationwide.
List of Lung Cancer Surgery Market in Canada Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, lung cancer surgery companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lung cancer surgery companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Lung Cancer Surgery Market in Canada by Segment
The study includes a forecast for the lung cancer surgery market in Canada by product type, surgery, and end use.
Lung Cancer Surgery Market in Canada by Product Type [Analysis by Value from 2019 to 2031]:
• Surgical Devices
• Endosurgical Equipment
• Monitoring or Visualizing Equipment
Lung Cancer Surgery Market in Canada by Surgery [Analysis by Value from 2019 to 2031]:
• Robotic Surgery
• Thoracotomy
• Video Assisted Surgery
• Percutaneous Surgery
• Endobronchial Surgery
Lung Cancer Surgery Market in Canada by End Use [Analysis by Value from 2019 to 2031]:
• Hospitals
• Specialty Cancer Care Centers
• Ambulatory Surgical Centers
• Others
Features of the Lung Cancer Surgery Market in Canada
Market Size Estimates: Lung cancer surgery in Canada market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Lung cancer surgery in Canada market size by product type, surgery, and end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different product type, surgery, and end use for the lung cancer surgery in Canada.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lung cancer surgery in Canada.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the lung cancer surgery market in Canada?
Answer: The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.
Q2. What are the major segments for lung cancer surgery market in Canada?
Answer: The future of the lung cancer surgery market in Canada looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets.
Q3. Which lung cancer surgery market segment in Canada will be the largest in future?
Answer: Lucintel forecasts that surgical device is expected to witness the highest growth over the forecast period.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the lung cancer surgery market in Canada by product type (surgical devices, endosurgical equipment, and monitoring or visualizing equipment), surgery (robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery, and endobronchial surgery), and end use (hospitals, specialty cancer care centers, ambulatory surgical centers, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Lung Cancer Surgery Market in Canada, Lung Cancer Surgery Market in Canada Size, Lung Cancer Surgery Market in Canada Growth, Lung Cancer Surgery Market in Canada Analysis, Lung Cancer Surgery Market in Canada Report, Lung Cancer Surgery Market in Canada Share, Lung Cancer Surgery Market in Canada Trends, Lung Cancer Surgery Market in Canada Forecast, Lung Cancer Surgery Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.